Signaling by FGFR2 amplification mutants

Stable Identifier
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser
FGFR2 amplifications have been identified in 10% of gastric cancers, where they are associated with poor prognosis diffuse cancers (Hattori, 1996; Ueda, 1999; Shin, 2000; Kunii, 2008) , and in ~1% of breast cancers (Turner, 2010; Tannheimer, 2000). FGFR2 amplification often occur in conjunction with deletions of C-terminal exons, resulting in expression of a internalization- and degradation-resistant form of the receptor (Takeda, 1999; Cha, 2008, 2009). Amplification affects signaling without altering the intrinsic kinase activity of the receptor. Signaling through overexpressed FGFR2 also shows evidence of being ligand-independent and sensitive to FGFR inhibitors (Lorenzi, 1997; Takeda, 1999; Cha, 2009).
Literature References
PubMed ID Title Journal Year
10626794 Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs

Sakamoto, H, Shibuya, T, Kuwahara, Y, Yanagihara, K, Nezu, M, Ishii, H, Sasaki, H, Terada, M, Makuuchi, M, Ueda, T, Mafune, K

Cancer Res 1999
18337450 Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis

Der, CJ, Cha, JY, Lambert, QT, Reuther, GW

Mol Cancer Res 2008
17505008 AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor

Fukuoka, K, Yamada, Y, Yanagihara, K, Nishio, K, Sasaki, H, Kimura, H, Takeda, M, Tamura, T, Komatsu, T, Yokote, H, Arao, T, Saijo, N

Clin Cancer Res 2007
9816310 Immunohistochemical detection of K-sam protein in stomach cancer

Sakamoto, H, Sugimura, T, Hattori, Y, Terada, M, Hirohashi, S, Uchino, S, Hosokawa, K, Yamaguchi, N, Ino, Y, Yanagihara, K, Itoh, H, Ishii, H, Ochiai, A

Clin Cancer Res 1996
20101236 Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

Geyer, FC, van Kouwenhove, M, van de Vijver, MJ, Horlings, HM, Reis-Filho, JS, Ashworth, A, Lambros, MB, Natrajan, R, Sharpe, R, Turner, N, Kreike, B, Mackay, A, Pearson, A

Oncogene 2010
19103595 Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform

Der, CJ, Harden, TK, Mitin, N, Cha, JY, Maddileti, S

J Biol Chem 2009
11003564 Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer

Shin, EY, Shin, KS, Lee, BH, Kim, EG, Yang, JH, Song, YJ, Lee, GK, Park, SC, Yun, HY

J Cancer Res Clin Oncol 2000
9266968 Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations

Miki, T, Chedid, M, Chen, Q, Lorenzi, MV, Castagnino, P

Oncogene 1997
18381441 FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

Kunii, K, Gorenstein, J, Hatch, H, Lutterbach, B, Yashiro, M, Davis, L, Di Bacco, A, Elbi, C

Cancer Res 2008
11056689 Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE

Rehemtulla, A, Ethier, SP, Tannheimer, SL

Breast Cancer Res 2000
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!